You are here: Home > News > Latest updates & news > Patient care & management > TGA approves AciVision to treat ocular herpes
Read time:


hero image

By Rhiannon Riches
Communications Manager

AciVision (Aciclovir) 3% (30mg/g) eye ointment 4.5g has received Therapeutic Goods Administration (TGA) approval for topical application for treatment of ocular herpes.

Optometry Australia understands that an ongoing supply will be available in Australia in the coming weeks.

This follows an announcement that Zovirax (Aciclovir) 3% eye ointment 4.5g, will cease production.

GlaxoSmithKline Australia, the manufacturer of Zovirax (Aciclovir), advised Optometry Australia that stocks in Australia are estimated to last until approximately December 2018.

AciVision is not currently listed on the PBS.

Filed in category: Patient care & management, Therapeutics
Tagged as:

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.